Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Oct;76(10):1267, 1269-70, 1272.
doi: 10.1007/s00115-005-1935-4.

[High-dose intravenous immunoglobulins in the treatment of multiple sclerosis. An update]

[Article in German]
Affiliations
Review

[High-dose intravenous immunoglobulins in the treatment of multiple sclerosis. An update]

[Article in German]
M Stangel et al. Nervenarzt. 2005 Oct.

Abstract

The immunomodulatory treatment of multiple sclerosis (MS) with high-dose intravenous immunoglobulins (IVIg) has been discussed with some controversy in the context of evidence-based medicine. The recent publication of eight trials investigating several aspects of MS has shed some more light on the role of IVIg treatment in MS. Here we summarize and critically discuss the new data in the context of previous studies on this treatment. In relapsing-remitting MS, IVIg remain a second-line treatment when other licensed treatments are not possible. Currently there is no role for IVIg in secondary progressive MS. Similarly, the use of IVIg during an acute relapse shows no benefit in addition to standard steroid treatment. The initiation of IVIg therapy after a clinically isolated syndrome has delayed the occurrence of definite MS, and this may become a new indication. Furthermore, previous data suggesting that IVIg can reduce the incidence of postpartal relapses have been substantiated. However, those trials unfortunately lack appropriate internal control groups. By and large, previous recommendations for the use of IVIg in MS are supported by the new data.

PubMed Disclaimer

References

    1. Eur J Obstet Gynecol Reprod Biol. 1999 Feb;82(2):191-4 - PubMed
    1. Lancet. 2004 Sep 25-Oct 1;364(9440):1149-56 - PubMed
    1. Neuroradiology. 2004 Apr;46(4):287-90 - PubMed
    1. N Engl J Med. 1998 Jul 30;339(5):285-91 - PubMed
    1. Nervenarzt. 2002 Jun;73(6):556-63 - PubMed

MeSH terms

Substances

LinkOut - more resources